Comparison

BIRC3 Antibody (N-term) Blocking peptide

Item no. ABC-BP14020a
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Zane, L., et al. Virology 407(2):341-351(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Kim, C.W., et al. Biochem. Biophys. Res. Commun. 400(1):46-52(2010)Petersen, S.L., et al. Proc. Natl. Acad. Sci. U.S.A. 107(26):11936-11941(2010)Friboulet, L., et al. BMC Cancer 10, 327 (2010) :
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias Baculoviral IAP repeat-containing protein 3,632-,Apoptosis inhibitor 2,API2,C-IAP2,IAP homolog C,Inhibitor of apoptosis protein 1,IAP-1,hIAP-1,hIAP1,RING finger protein 49,TNFR2-TRAF-signaling complex protein 1,BIRC3,API2,IAP1,MIHC,RNF49
Similar products BIRC3, API2, IAP1, MIHC, RNF49, Baculoviral IAP repeat-containing protein 3, Apoptosis inhibitor 2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, RING finger protein 49, TNFR2-TRAF-signaling complex protein 1, IAP-1, 632-, hIAP-1, hIAP1
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence used to generate the antibody AP14020a was selected from the N-term region of BIRC3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background
The protein encoded by this gene is a member of a familyof proteins that inhibits apoptosis by binding to tumor necrosisfactor receptor-associated factors TRAF1 and TRAF2, probably byinterfering with activation of ICE-like proteases. The encodedprotein inhibits apoptosis induced by serum deprivation but doesnot affect apoptosis resulting from exposure to menadione, a potentinducer of free radicals. The amino acid sequence predicts threebaculovirus IAP repeat domains and a ring finger domain. Transcriptvariants encoding the same isoform have been identified. [providedby RefSeq].
Gene Name
BIRC3
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close